December 7, 2023
Authored and Edited by Douglas W. Cheek; Ryan V. McDonnell; Elizabeth D. Ferrill
In Purdue Pharma L.P. v. Collegium Pharmaceutical, Inc., No. 22-1482 (Fed. Cir. Nov. 21, 2023), the Federal Circuit held that the Patent Trial and Appeal Board (“Board”) has authority to issue a Final Written Decision (“FWD”) after the deadline proscribed by 35 U.S.C. § 326(a)(11) and 37 C.F.R. § 42.200(c) and affirmed the Board’s finding that claims 1-17 of U.S. Patent No. 9,693,961 are invalid for lack of written description.
The Board took over 37 months from institution to issue its FWD. Purdue appealed the Board’s decision, arguing that the Board lacked authority to issue a FWD beyond the 18-month deadline after institution to do so. The Federal Circuit evaluated the statute’s language, structure, and legislative history and concluded that because § 326(a)(11) does not specify any consequences for non-compliance with the 18-month deadline, the Board had authority to issue a FWD after the deadline. This holding was consistent with Supreme Court precedent regarding other statutes without any specified consequences for non-compliance with a deadline. The Federal Circuit cautioned, however, that the Board “may not ignore statutory deadlines” and that the “appropriate remedy is mandamus.”
Patent Trial and Appeal Board (PTAB), rules and rules of practice, IPR estoppel, validity, Written description (35 USC § 112), America Invents Act (AIA)
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
USPTO Releases Notice of Proposed Rule Making Codifying Several Precedential Case Factors
April 25, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.